Bepirovirsen clinical trials
Also written GSK3228836.
How each study uses bepirovirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bepirovirsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Oct 2026 · HIBSAGO · NDA 221276 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 1
GlaxoSmithKline (15) · National University Health System, Singapore (1)
Often tested with
Tested in the same studies.
GSK-3965193 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test bepirovirsen.
- Mar 2027A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsPhase 1 · GlaxoSmithKline
- Apr 2027Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)Phase 2 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses bepirovirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study ParticipantsNot yet recruitingPhase 4GlaxoSmithKlineNCT07908459Written as Bepirovirsen
- A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsNot yet recruitingPhase 1GlaxoSmithKlineNCT07905157Written as Bepirovirsen
- Bepirovirsen Liver Biopsy StudyNot yet recruitingPhase 2National University Health System, SingaporeNCT07696520Written as Bepirovirsen
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)Active, not recruitingPhase 2GlaxoSmithKlineNCT06497504Written as Bepirovirsen
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)Active, not recruitingPhase 2GlaxoSmithKlineNCT04954859Written as Bepirovirsen
- Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B InfectionTerminatedPhase 1/2GlaxoSmithKlineNCT05330455Written as Bepirovirsen
- Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT06422767Written as Bepirovirsen
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)CompletedPhase 3GlaxoSmithKlineNCT05630820Written as Bepirovirsen
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)CompletedPhase 3GlaxoSmithKlineNCT05630807Written as Bepirovirsen
- A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney DiseaseActive, not recruitingPhase 1GlaxoSmithKlineNCT07168356Written as Bepirovirsen
- A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT06058390Written as Bepirovirsen
- A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis BCompletedPhase 2GlaxoSmithKlineNCT04544956Written as GSK3228836
- Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)CompletedPhase 2GlaxoSmithKlineNCT04676724Written as GSK3228836
- A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)CompletedPhase 2GlaxoSmithKlineNCT04449029Written as GSK3228836
- Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic ImpairmentCompletedPhase 1GlaxoSmithKlineNCT04971928Written as GSK3228836
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV InfectionCompletedPhase 2GlaxoSmithKlineNCT02981602Written as IONIS-HBVRx
Given beside what is tested · 2 — bepirovirsen is usual care or a partner of the new treatment
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)Active, not recruitingPhase 2GlaxoSmithKlineNCT06537414Written as Bepirovirsen
- A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) TherapyCompletedPhase 2GlaxoSmithKlineNCT05276297Written as GSK3228836
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call bepirovirsen · ClinicalTrials.gg INT018668
- UNII (FDA) Z87O6SM01NBEPIROVIRSENOne source FDA
- NCI Thesaurus C175748BepirovirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z87O6SM01N | BEPIROVIRSEN | One source FDA |
| NCI Thesaurus | C175748 | Bepirovirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.